• Biosimilar Hyrimoz^® (adalimumab) approved for use in all same indications as reference medicine*** including rheumatology, gastroenterology and dermatology
• Early therapeutic intervention is essential in rheumatoid arthritis, supporting urgency of treatments like Hyrimoz
• Fourth Sandoz biosimilar approved in Europe** in past 18 months, and seventh in total, underscoring Sandoz commitment to making access happen through a robust portfolio

Holzkirchen, July 27, 2018 – Sandoz, a Novartis division …